Publications and Presentations (as of Nov. 12, 2017):

**Neuromuscular Disease**

Becker RV. Potential Benefits of Pegylation in the Treatment of Multiple Sclerosis: A Systematic Review of the Pharmacoeconomic Literature. 15th European Federation of Neurorological Societies Congress, Budapest, September 2011 (Abs.).


Becker RV, Dembek C. Data Selection Considerations in Cost-Effectiveness Analyses in Multiple Sclerosis. 63rd Annual Meeting of the American Academy of Neurology (AAN), Honolulu April 2011 (abs.)


**Pain Management/Osteoarthritis**

Becker R, Miller K, McIntosh J, Miller J, Sweeney M. Budget impact and cost-effectiveness of once-daily gabapentin for the treatment of postherpetic neuralgia. ISPOR International Conference, June 2012 (Abs.).


Becker RV, Wong A, Forte L, Miller B. An economic evaluation of the cost of cardiorenal and gastrointestinal events in elderly coxib-treated patients, Canadian Association of Population Therapeutics Annual Meeting, Quebec City, Canada, March 2003 (Abs.).


**Urology/Overactive Bladder**


Albo M, Rovner E, Mullins C, Becker R, Jumadilova Z, Benner J. Overactive bladder symptom bother is more prevalent in men than women at older ages. Poster presented at American Urology Association Western Section Meeting, October 2006 (Abs., Third place award.)


Becker RV, Noe LL, Chen DM, Williamson T. Evaluating the cost of long-acting treatments for overactive bladder.


**Oncology**


**Gastrointestinal**

HIV/AIDS

Becker, RV, Teich, V, Pepe, C. National cost savings from Brazil’s HIV/AIDS antiretroviral universal access program: analysis versus Canada and Australia. ISPOR European Conference, Nov. 2011 (Abs.).

Teich, V, Becker, RV, Pepe, C. National cost savings from Brazil’s HIV/AIDS antiretroviral universal access program. 8th Annual Health Technology Assessment International (HTAi) Conference, Rio de Janeiro, Brazil, June 27, 2011 (Abs.).


Becker RV, Zaccagnini P, Rattana S. Impact of adopting Brazil’s antiretroviral drug pricing in three Central American countries. Proceedings of the XIV International Conference on AIDS; 2002 Jul; Barcelona, Spain (Abs.).

Becker RV, Shakur I. Cost-effectiveness of salvage therapy with delavirdine in NNRTI-naïve patients failing indinavir. Proceedings of the XIV International Conference on AIDS; 2002 Jul; Barcelona, Spain (Abs.).


Cardiovascular

Deitelzweig S, Lin J, Benner J, Becker R. Comparison of the two-year clinical outcomes of VTE prophylaxis options in medical patients at risk of VTE. Annual American Society of Hypertension Meeting, May 2008 (Abs.).

Deitelzweig S, Lin J, Benner J, Becker R. Two-year costs of enoxaparin prophylaxis, unfractionated heparin prophylaxis, or no prophylaxis in medical patients at risk of venous thromboembolism. Annual Society of Hospital Medicine Meeting, April 2008 (Abs.).


**Attention Deficit Hyperactivity Disorder (ADHD)**


**Drug Delivery**


**Mental Health**


**HEOR Methodology**


Becker R. Building a Budget Impact Model (Podium Presentation), First Educational Workshop of Lebanese Chapter of ISPOR, Beirut, Lebanon, November, 2016.

Schultz N, Becker R. Variances in the rate of face, internal, and third party model validity by type of publication, type of model and geographic region. 18th Annual ISPOR International Conference, June 2013, New Orleans, Louisiana (Abs.).

Becker R. Third Party Model Validity: A review and survey of face and internal validity of health economic models. ISPOR European Conference, November 2012 (abs.)
